🔎 Trials Near Me

Home › Astrocytoma

Astrocytoma clinical trials recruiting in the U.S.

45 studies for Astrocytoma are recruiting participants at sites across the United States.

Cities with the most studies

By state

Recently updated studies

MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT06047379

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

RecruitingPhase 2
Ages 18 to 98 · All sexes · Updated Sep 21, 2026 · NCT07831369

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma

RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 14, 2026 · NCT05698524

SJ901: Evaluation of Mirdametinib in Children, Adolescents, and Young Adults With Low-Grade Glioma

RecruitingPhase 1/2
Ages 2 to 24 · All sexes · Updated Sep 11, 2026 · NCT04923126

FearLess in NeuroOncology

Recruiting
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06989086

Targeted Pediatric High-Grade Glioma Therapy

RecruitingObservational study
12 Months – 39 Years · All sexes · Updated Sep 8, 2026 · NCT05839379

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors

RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT06860594

Serial MRI Scans During Radiation Therapy

Recruiting
Ages 18 and older · All sexes · Updated Sep 2, 2026 · NCT04188535

Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

RecruitingPhase 3
Ages 12 and older · All sexes · Updated Sep 2, 2026 · NCT07215910

Study of Olutasidenib and Temozolomide in HGG

RecruitingPhase 2
Ages 12 to 39 · All sexes · Updated Sep 1, 2026 · NCT06161974

SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT05303519

Hypofractionation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma

RecruitingPhase 1
Ages 18 to 120 · All sexes · Updated Aug 14, 2026 · NCT06344130

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies

RecruitingPhase 1/2
Ages 18 to 130 · All sexes · Updated Aug 12, 2026 · NCT05417594

Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas

RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jul 16, 2026 · NCT04623931

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

RecruitingEarly phase 1Healthy volunteers welcome
Ages 1 to 21 · All sexes · Updated Jun 29, 2026 · NCT06333899

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 24, 2026 · NCT07468136

A Study of 177Lu-PSMA-617 in People With Gliomas

RecruitingPhase 1
Ages 18 and older · All sexes · Updated Jun 4, 2026 · NCT07223034

Loupe-Based Intraoperative Fluorescence Imaging

RecruitingObservational study
Ages 18 to 90 · All sexes · Updated Jun 3, 2026 · NCT04780009

Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA

RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jun 1, 2026 · NCT01269853

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.